Open Access<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>
Author(s) -
Guanzhang Li,
Kenan Zhang,
Zheng Wang,
Huimin Hu,
Zhiliang Wang,
Ruoyu Huang,
Haiyan Jiang,
You Zhai,
Yuemei Feng,
Yuanhao Chang,
Renpeng Li,
Fan Wu,
Fan Zeng,
Tao Jiang,
Wei Zhang
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s223406
Subject(s) - immunotherapy , glioma , medicine , immune system , immune checkpoint , cancer research , immunology
Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppression. We aimed to study the characteristics and immune function of Siglec family members.